HER2-Negative Breast Cancer

Anthracycline-based Regimens Superior in Treating High-Risk, HER2-negative Breast Cancer

Anthracycline-based Regimens Superior in Treating High-Risk, HER2-negative Breast Cancer

By

Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.

Clinical trial results of nintedanib for HER2-negative breast cancer are promising

By

The experimental drug nintedanib, in combination with standard paclitaxel chemotherapy, caused a total remission of tumors in half of patients with early stage HER2-negative breast cancer.

Guidelines issued for HER2-negative breast cancer

Guidelines issued for HER2-negative breast cancer

Evidence-based recommendations have been developed for chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer.

New test predicts if breast cancer will spread

New test predicts if breast cancer will spread

By

A test of tumor microenvironment of metastasis (TMEM) predicted risk of distant metastasis in estrogen receptor-positive and HER2-negative breast cancer, according to a new study.

High-fat diet tied to breast cancer subtypes

High-fat diet tied to breast cancer subtypes

High intake of saturated fat increases risk of HER2-negative, ER/PR-positive disease.

Dasatinib with letrozole delays disease progression for some metastatic breast cancer

By

Adding dasatinib to the standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer. These results of a phase 2 clinical trial were presented at the 2013 San Antonio Breast Cancer Symposium.

Ramucirumab combination therapy failed to delay progression of advanced breast cancer

By

Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.

New presurgery combination therapy promising for triple-negative breast cancer

By

I-SPY 2 has yielded positive results with the first drug to complete testing during the trial. Adding carboplatin and veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results presented at the 2013 San Antonio Breast Cancer Symposium.

ASCO/CAP update advice on HER2 testing in breast cancer

By

All persons with invasive breast cancer (early stage or recurrence) should undergo testing for human epidermal growth factor receptor 2 (HER2), and at least one tumor sample should be tested for either HER2 protein expression or HER2 gene amplification.

Trastuzumab: not just for HER2-positive breast cancer anymore?

The monoclonal antibody trastuzumab (Herceptin) may be effective against HER2-negative breast cancers in addition to HER2-positive disease.

Trastuzumab may also be effective for women with HER2-negative breast cancer

By

The protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative. The drug trastuzumab (Herceptin), which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.

Gene expression improves definition of hormone-sensitive breast cancer subtype

By

The definition of hormone-sensitive breast tumors known as luminals has been changed by a recent study.

Eribulin may be useful earlier in breast cancer

A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.

Some breast cancers may respond to anti-androgen drug

By

Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.

Drug combo shows promise in triple-negative breast cancer

Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.

Excess weight bodes poorly for HR-positive breast cancer

Overweight and obese women with hormone receptor (HR)-positive operable breast cancer have an increased risk of disease recurrence and death.

Common diabetes drug appears to lower breast cancer risk

Metformin, prescribed to help control blood glucose levels in type 2 diabetes, may play a role in the prevention or management of breast cancer.

VEGF blockade: Optimizing chemotherapy drug uptake

VEGF blockade: Optimizing chemotherapy drug uptake

By

New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.

PET clarifies difficult breast cancer cases

By

Positron emission tomography (PET) can help pinpoint a breast cancer diagnosis and predict prognosis in an aggressive form of the disease.

Bevacizumab Efficacious for HER2-Negative Breast Cancer

Bevacizumab Efficacious for HER2-Negative Breast Cancer

Two studies show improved pathologic complete response with addition of bevacizumab.

LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication

The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.

After a Breast Cancer Diagnosis: Questions to Ask Your Doctor

After a Breast Cancer Diagnosis: Questions to Ask Your Doctor

This patient fact sheet provides questions you may want to ask your doctor about the results of your diagnostic tests and explains the significance of the answers to the questions.

FDA group stands against bevacuzimab for breast cancer

The Oncologic Drug Advisory Committee recommended that the FDA withdraw its approval of bevacizumab's indication for breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs